AR058347A1 - Entidades quimias composiciones y metodos - Google Patents

Entidades quimias composiciones y metodos

Info

Publication number
AR058347A1
AR058347A1 ARP060105509A ARP060105509A AR058347A1 AR 058347 A1 AR058347 A1 AR 058347A1 AR P060105509 A ARP060105509 A AR P060105509A AR P060105509 A ARP060105509 A AR P060105509A AR 058347 A1 AR058347 A1 AR 058347A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
heterocycloalkyl
heteroaryl
alkoxy
halo
Prior art date
Application number
ARP060105509A
Other languages
English (en)
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AR058347A1 publication Critical patent/AR058347A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Derivados de urea substituida que modulan selectivamente el sarcomero cardíaco, y son utiles en el tratamiento de la falla cardíaca sistolica y la falla cardíaca congestiva. Reivindicacion 1: Un método para aumentar el alcance pero no la velocidad de la contraccion cardíaca que comprende administrar al menos una entidad química elegida de los compuestos de la formula (1) y las sales farmacéuticamente aceptables, quelatos, complejos no covalentes, pro-fármacos, y las mezclas de los mismos, en donde W, X, Y, y Z son independientemente -C= o -N=, siempre que no más de dos W, X, Y, y Z sean -N=; n es 1, 2 o 3; R1 es amino opcionalmente substituido o heterocicloalquilo opcionalmente substituido; R2 es arilo opcionalmente substituido, aralquilo opcionalmente substituido, cicloalquilo opcionalmente substituido, heteroarilo opcionalmente substituido, heteroaralquilo opcionalmente substituido o heterocicloalquilo opcionalmente substituido; R3 es H, halo, ciano, alquilo opcionalmente sustituido, alcoxi opcionalmente substituido, heterocicloalquilo opcionalmente substituido, o heteroarilo opcionalmente substituido cuando W es -C=, y R3 está ausente cuando W es -N=; R4 es H, halo, ciano, alquilo opcionalmente sustituido, alcoxi opcionalmente substituido, heterocicloalquilo opcionalmente substituido, o heteroarilo opcionalmente substituido cuando Y es -C=, y R4 está ausente cuando Y es -N=; R5 es H, halo, ciano, alquilo opcionalmente sustituido, alcoxi opcionalmente substituido, heterocicloalquilo opcionalmente substituido, o heteroarilo opcionalmente substituido cuando X es -C=, y R5 está ausente cuando X es -N=; R13 es H, halo, ciano, hidroxil, alquilo opcionalmente sustituido, alcoxi opcionalmente substituido, heterocicloalquilo opcionalmente substituido, o heteroarilo opcionalmente substituido cuando Z es -C=, y R13 está ausente cuando Z es -N=; R6 y R7 son independientemente H, aminocarbonil, alcoxicarbonil, alquilo opcionalmente sustituido o alcoxi opcionalmente substituido, o R6 y R7 tomados juntos con el C al cual se unen, forman un anillo de 3 a 7 miembros opcionalmente substituido que opcionalmente incorpora 1 o 2 heteroátomos adicionales, seleccionados de N, O, y S en el anillo; y R18 y R19 son independientemente elegidos del H, alquilo opcionalmente sustituido, cicloalquilo opcionalmente substituido, heterocicloalquilo opcionalmente substituido, arilo opcionalmente substituido, y heteroarilo opcionalmente substituido.
ARP060105509A 2005-12-15 2006-12-14 Entidades quimias composiciones y metodos AR058347A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75140005P 2005-12-15 2005-12-15
US75635606P 2006-01-04 2006-01-04
US81797506P 2006-06-29 2006-06-29

Publications (1)

Publication Number Publication Date
AR058347A1 true AR058347A1 (es) 2008-01-30

Family

ID=38163546

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105509A AR058347A1 (es) 2005-12-15 2006-12-14 Entidades quimias composiciones y metodos

Country Status (8)

Country Link
US (3) US20070161617A1 (es)
EP (1) EP1959960B1 (es)
JP (1) JP5301284B2 (es)
AR (1) AR058347A1 (es)
ES (1) ES2419007T3 (es)
PE (1) PE20071161A1 (es)
TW (1) TW200808321A (es)
WO (1) WO2007070683A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004206860B2 (en) * 2003-01-14 2010-03-18 Cytokinetics, Inc. Compounds, compositions and methods
SG149027A1 (en) 2004-06-17 2009-01-29 Cytokinetics Inc Substituted urea derivatives for treating cardiac diseases
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
WO2007070683A2 (en) 2005-12-15 2007-06-21 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
AU2014239995B2 (en) * 2013-03-14 2018-07-26 Amgen Inc. Salt of omecamtiv mecarbil and process for preparing salt
EP2968180B1 (en) * 2013-03-14 2019-04-24 Amgen Inc. Heterocyclic compounds and their uses
HUE055242T2 (hu) 2017-06-30 2021-11-29 Amgen Inc Omecamtiv mecarbil szintézise
EP3645002A1 (en) 2017-06-30 2020-05-06 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
IL272573B2 (en) 2017-09-13 2023-10-01 Amgen Inc Sarcomere activating bisamide compounds and their uses
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
CN110124046B (zh) * 2019-06-11 2023-04-07 辽宁大学 一种氧化石墨烯负载双氯芬酸二乙胺及其制备方法
US20230090391A1 (en) * 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
US11702380B2 (en) 2021-03-10 2023-07-18 Amgen Inc. Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL254871A (es) 1959-08-14
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
US3939169A (en) * 1971-03-29 1976-02-17 Imperial Chemical Industries Limited Alkylene bis(pyridiniumareylene quaternary salts)
DE2942930A1 (de) 1979-10-24 1981-05-27 Basf Ag, 6700 Ludwigshafen Substituierte harnstoffe, deren herstellung und verwendung als herbizide
EP0081142B1 (de) 1981-12-03 1986-06-25 BASF Aktiengesellschaft 1,3,5-Triazinone, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
DE3147879A1 (de) 1981-12-03 1983-06-16 Basf Ag, 6700 Ludwigshafen 1,3,5-triazinone, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
AU2818584A (en) 1983-03-29 1984-10-25 Fmc Corporation N-phenyl-n-(pyridinyl-n-oxide)urea plant regulators
US4787931A (en) 1984-03-06 1988-11-29 Fmc Corporation N-phenyl-N'-(pyridinyl-N-oxide)urea plant regulators
US4672066A (en) 1985-04-22 1987-06-09 Hoffmann-La Roche Inc. Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GB9201180D0 (en) 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
KR950701621A (ko) * 1992-05-28 1995-04-28 알렌 제이. 스피겔 아실 조효소a : 콜레스테롤 아실 전이효소(acat)의 억제제로서 신규한 n- 아릴 및 n- 헤테로아릴우레아 유도체(new n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a : cholesterol acyl transferase(acat)
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0634402A1 (en) 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
EP0784612A1 (en) 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
ES2218554T3 (es) 1994-10-27 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina.
US6010026A (en) 1994-11-22 2000-01-04 Aluminum Company Of America Assembly of aluminum can and threaded sleeve
US5556969A (en) 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6005008A (en) 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
CA2261031A1 (en) 1996-07-23 1998-01-29 Charles A. Blum Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
AUPO390996A0 (en) 1996-11-29 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998041510A1 (fr) 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Nouveaux derives du benzolactame et compositions medicamenteuses les contenant
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
WO1998052559A1 (en) 1997-05-23 1998-11-26 Bayer Corporation Raf kinase inhibitors
DE69809967T2 (de) * 1997-11-05 2003-09-11 Choongwae Pharma Corp Genipin-derivate mit einer die leber schützenden aktivität
KR100571588B1 (ko) 1997-12-22 2006-04-17 바이엘 코포레이션 치환 헤테로시클릭 우레아를 이용한 ｒａｆ 키나제의 억제
JP4403482B2 (ja) 1997-12-22 2010-01-27 バイエル コーポレイション 置換複素環尿素合成のための中間体およびその製造方法
EP1042305B1 (en) 1997-12-22 2005-06-08 Bayer Pharmaceuticals Corp. INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
MXPA00006231A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de raf-cinasa usando difenil ureas sustituidas, simetricas y asimetricas.
JP4405602B2 (ja) 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
AU4317899A (en) 1998-06-08 1999-12-30 Schering Corporation Neuropeptide y5 receptor antagonists
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
JP3594317B2 (ja) 1998-08-11 2004-11-24 住友製薬株式会社 ナフチリジン誘導体
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2000052004A1 (en) 1999-03-01 2000-09-08 The Regents Of The University Of California Thiacrown polymers for removal of mercury from waste streams
DE19921498A1 (de) * 1999-05-08 2000-11-16 Clariant Gmbh Verfahren zur Herstellung von wäßrigen Diazoniumsalzlösungen
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
EP1199306B1 (en) 1999-07-26 2005-12-07 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
CA2385972A1 (en) 1999-10-01 2001-04-12 Haruhisa Ogita Novel diarylamide derivatives and use thereof as medicines
AU1617901A (en) 1999-11-16 2001-05-30 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001098269A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
GB0015904D0 (en) 2000-06-28 2000-08-23 Hoffmann La Roche Inhibitors of HPV E1 helicase enzyme
JP5079202B2 (ja) 2000-07-18 2012-11-21 大日本住友製薬株式会社 セロトニン再取り込み阻害剤
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
JP2004532187A (ja) * 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
JP2002220338A (ja) 2001-01-26 2002-08-09 Banyu Pharmaceut Co Ltd ビアリールウレア化合物又はその塩を有効成分として含有するＣｄｋ４及び／又はＣｄｋ６阻害剤
GB0117950D0 (en) 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
JP4366936B2 (ja) 2001-04-20 2009-11-18 バイエル コーポレイション キノリル、イソキノリルまたはピリジル尿素を使用するｒａｆキナーゼの阻害
EP1392661A1 (en) 2001-05-16 2004-03-03 Boehringer Ingelheim Pharmaceuticals Inc. Diarylurea derivatives useful as anti-inflammatory agents
EP1395561A1 (en) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
AU2002346048A1 (en) 2001-06-07 2002-12-16 Merck And Co., Inc. Benzodiazepine bradykinin antagonists
EP1408950B1 (en) * 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
WO2003022820A1 (en) 2001-09-06 2003-03-20 Bristol-Myers Squibb Pharma Company. Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
WO2003024933A1 (fr) 2001-09-12 2003-03-27 Kaken Pharmaceutical Co., Ltd. Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6908923B2 (en) 2001-12-21 2005-06-21 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003062224A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
EP1472248A1 (en) 2002-01-17 2004-11-03 Eli Lilly And Company Modulators of acetylcholine receptors
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
DE10208986A1 (de) 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
US20050171358A1 (en) 2002-03-07 2005-08-04 Noriko Shimozono Substituted isoxazole alkylamine derivative and agri-and horticultural fungicide
PL372919A1 (en) 2002-03-28 2005-08-08 Applied Research Systems Ars Holding N.V. Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
AU2003220935A1 (en) 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
PL373889A1 (en) 2002-04-18 2005-09-19 Schering Corporation (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
DE60325469D1 (de) 2002-04-23 2009-02-05 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1506157A2 (en) 2002-05-17 2005-02-16 Lica Pharmaceuticals A/S Amino-functional chalcones
US6693576B2 (en) * 2002-05-23 2004-02-17 Tektronix, Inc. Methods and apparatus providing multiple concurrent acquisition modes in a digitizing measurement instrument
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
ATE344798T1 (de) 2002-06-24 2006-11-15 Schering Corp Als histamin-h3-antagonisten geeignete indolderivate
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
AU2003281855A1 (en) 2002-07-31 2004-02-23 Schering Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
GB0218147D0 (en) 2002-08-05 2002-09-11 Oxford Glycosciences Uk Ltd Novel compounds
WO2004019958A1 (ja) 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
EP1537116B1 (en) 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
AU2003255993A1 (en) 2002-09-10 2004-04-30 Pfizer Products Inc. Diazabicyclic compounds useful in the treatment of cns and other disorders
AU2003285454A1 (en) 2002-10-29 2004-05-25 L'oreal Hair treatment composition containing a styryl-pyrazole compound
AU2004206860B2 (en) * 2003-01-14 2010-03-18 Cytokinetics, Inc. Compounds, compositions and methods
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
AU2003902073A0 (en) 2003-05-01 2003-05-15 Kevin Raymond Deguara A lighting substrate
ATE462432T1 (de) 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
WO2004101529A1 (ja) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
US7235353B2 (en) 2003-07-18 2007-06-26 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
PE20051046A1 (es) * 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US7880000B2 (en) 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
SG149027A1 (en) * 2004-06-17 2009-01-29 Cytokinetics Inc Substituted urea derivatives for treating cardiac diseases
US7176222B2 (en) * 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1959947A2 (en) 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007070683A2 (en) 2005-12-15 2007-06-21 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US7672247B2 (en) * 2006-02-23 2010-03-02 International Business Machines Corporation Evaluating data processing system health using an I/O device

Also Published As

Publication number Publication date
WO2007070683A2 (en) 2007-06-21
US20130324549A1 (en) 2013-12-05
WO2007070683A3 (en) 2008-11-20
US8445495B2 (en) 2013-05-21
ES2419007T3 (es) 2013-08-19
US20100029680A1 (en) 2010-02-04
JP5301284B2 (ja) 2013-09-25
EP1959960B1 (en) 2013-04-10
PE20071161A1 (es) 2008-02-03
JP2009519951A (ja) 2009-05-21
EP1959960A2 (en) 2008-08-27
TW200808321A (en) 2008-02-16
US8871768B2 (en) 2014-10-28
US20070161617A1 (en) 2007-07-12
EP1959960A4 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
AR058347A1 (es) Entidades quimias composiciones y metodos
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
NO20064251L (no) Benzamidazolderivater og anvendelse derav
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
PE20081530A1 (es) Nuevos compuestos 617
EA200800285A1 (ru) Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
NO20076478L (no) Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20090042A1 (es) Analogos de ciclopamina
CY1111425T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ
ATE556058T1 (de) 1-(2h)-isochinolonderivat
HUP0402107A2 (hu) N-helyettesített pirrolidinszármazékok, mint dipeptidil-peptidáz IV inhibítorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TW200635585A (en) Monocyclic substituted methanones
SMT201300085B (it) Composti di pirrolo
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
NO20070606L (no) Inhibitorer av IAP
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
AR036672A1 (es) Derivados de pirrolidinona
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
AR050435A1 (es) DERIVADOS DE HIDROXIAMIDA, PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
RU2008119994A (ru) Ингибиторы калиевых каналов
NO20053715L (no) 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk

Legal Events

Date Code Title Description
FB Suspension of granting procedure